Page 109 - MEMORIA_SEHH-FEHH_2023

MEMORIA ANUAL 2023
SOCIEDAD ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
PETHEMA
FUNDACIÓN ESPAÑOLA DE
HEMATOLOGÍA Y HEMOTERAPIA
Pósteres
Congresos internacionales
• Epigenetic regulation of CD155 on multiple myeloma cells influences anti-tumor
novel immunotherapeutic approaches.
28th Congress of the European Hematology Association (EHA). EHA2023 Frankfurt &
Virtual, Jun (8-11) (P822).
Martínez-Verbo L, Villanueva L, Llinàs-Arias P, García-Prieto CA, Piñeyro D, Oliver-Caldes A,
García-Ortiz A, Valeri A, Fernández de Larrea C, Martínez-López J, Ferrer Manel Esteller G.
• Assessment of conventional translocations and Ig rearrangements in the diagnosis of
multiple myeloma patients using a targeted capture-hybridization RNA sequencing panel.
28th Congress of the EHA. EHA2023 Frankfurt & Virtual, Jun (8-11) (P840).
Buenache Cuenda N, Sánchez R, Giménez Sánchez A, Carneros Blanco L, Alonso Fernán-
dez R, Sánchez Pina JM, Rapado Martínez I, Ayala Díaz R, Martínez-López J, Rosa Rosa JM.
• Generation of a first-in-class inhibitor for the master oncoregulator HNRNP K in hae-
matological malignancies.
28th Congress of the EHA. EHA2023 Frankfurt & Virtual, Jun (8-11) (P846).
Otero-Sobrino A, Le Coq J, Aguilar-Garrido P, Navarro Aguadero MA, Hernández-Sán-
chez M, Albarrán MI, Klett J, Blanco C, Fernández Leiro R, Martínez-López J, Velasco
Estévez M, Gallardo M.
• Expression profile of BCL-2 family proteins in multiple myeloma.
28th Congress of the EHA. EHA2023 Frankfurt & Virtual, Jun (8-11) (P848).
De Ramón Sánchez C, A Rojas E, Misiewicz-Krzeminska I, Cardona-Benavides IJ, Cuadra-
do M, Isidro I, Calasanz MJ, García-Sanz R, Rosiñol Dachs L, Martínez-López J, Bladé J,
Lahuerta JJ, San Miguel JF, Mateos MV, Corchete LA, Gutiérrez Gutiérrez NC.
• The effect of urolithin production by gut microbiota in multiple myeloma.
28th Congress of the EHA. EHA2023 Frankfurt & Virtual, Jun (8-11) (P850).
Rodríguez-García A, García-Vicente R, Ancos R, Ortiz-Ruiz A, Navarro MA, Arroyo A, Mo-
rales Fernández ML, Guevara-Ramírez P, Justo P, Selma V, Tomás-Barberán FA, Ayala
Díaz R, Martínez-López J, Linares M.
• Selinexor in combination with daratumumab-bortezomib and dexamethasone for
the treatment of relapse or refractory multiple myeloma: updated results of the phase
2, multicenter GEM-SELIBORDARA study.
109